Global Transcriptomics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Global Transcriptomics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

  • Healthcare
  • Nov 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Author : Sachin Pawar

Circumvent the Tariff challenges with an agile supply chain Consulting

Supply Chain Ecosystem Analysis now part of DBMR Reports

Global Transcriptomics Market

Market Size in USD Billion

CAGR :  % Diagram

Bar chart comparing the Global Transcriptomics Market size in 2024 - 8.37 and 2032 - 17.54, highlighting the projected market growth. USD 8.37 Billion USD 17.54 Billion 2024 2032
Diagram Forecast Period
2025 –2032
Diagram Market Size (Base Year)
USD 8.37 Billion
Diagram Market Size (Forecast Year)
USD 17.54 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Agilent TechnologiesInc.
  • IlluminaInc.
  • F. Hoffmann-La Roche Ltd
  • Beckman CoulterInc.
  • Thermo Fisher Scientific Inc.

Global Transcriptomics Market Segmentation, By Product and Services (Instruments, Consumables, Software, and Services), Technology (Microarray, Real Time-PCR (qPCR), and Sequencing), Application (Diagnostics and Disease Profiling, Drug Discovery, and Others), End User (Pharmaceutical and Biotechnology Companies, Government Institutes and Academic Centers, and Contract Research Organizations (CROs)) - Industry Trends and Forecast to 2032

Transcriptomics Market Z

Transcriptomics Market Size

  • The global transcriptomics market size was valued at USD 8.37 billion in 2024 and is expected to reach USD 17.54 billion by 2032, at a CAGR of 9.68% during the forecast period
  • The market growth is largely fueled by the increasing adoption of high-throughput sequencing technologies and advancements in bioinformatics, leading to widespread application of transcriptomics in drug discovery, disease diagnostics, and personalized medicine
  • Furthermore, the rising demand for comprehensive gene expression analysis and precision therapeutics is establishing transcriptomics as a critical tool in molecular biology and clinical research. These converging factors are accelerating the uptake of transcriptomics solutions, thereby significantly boosting the industry's growth

Transcriptomics Market Analysis

  • Transcriptomics, the study of RNA transcripts, is becoming an increasingly vital component of modern life sciences and precision medicine due to its ability to provide deep insights into gene expression, regulatory mechanisms, and disease pathways across various biological systems
  • The escalating demand for transcriptomics solutions is primarily fueled by the rising prevalence of chronic diseases, the surge in personalized medicine initiatives, and growing research in oncology, immunology, and neurobiology
  • North America dominates the transcriptomics market with the largest revenue share of 38.5% in 2024, attributed to the region’s robust research infrastructure, strong funding support from government and private sectors, and widespread adoption of advanced sequencing technologies, with the U.S. leading in transcriptomics-based clinical and academic research
  • Asia-Pacific is expected to be the fastest growing region with a CAGR of 13.4% in the transcriptomics market during the forecast period, driven by expanding biotechnology sectors, increasing government investments in genomics, and the rising number of clinical trials and pharmaceutical R&D activities in countries such as China, India, and South Korea
  • The consumables segment dominates the transcriptomics market with a market share of 38.6% in 2024, primarily due to the high recurring demand for reagents, kits, and probes in transcriptomic workflows, particularly in large-scale gene expression studies and clinical diagnostics

Report Scope and Transcriptomics Market Segmentation    

Attributes

Transcriptomics Key Market Insights

Segments Covered

  • By Product and Services: Instruments, Consumables, Software, and Services
  • By Technology: Microarray, Real Time-PCR (qPCR), and Sequencing
  • By Application: Diagnostics and Disease Profiling, Drug Discovery, and Others
  • By End User: Pharmaceutical and Biotechnology Companies, Government Institutes and Academic Centers, and Contract Research Organizations (CROs)

Countries Covered

North America

  • U.S.
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • U.K.
  • Netherlands
  • Switzerland
  • Belgium
  • Russia
  • Italy
  • Spain
  • Turkey
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of Asia-Pacific

Middle East and Africa

  • Saudi Arabia
  • U.A.E.
  • South Africa
  • Egypt
  • Israel
  • Rest of Middle East and Africa

South America

  • Brazil
  • Argentina
  • Rest of South America

Key Market Players

Market Opportunities

  • Expansion of Personalized Medicine and Targeted Therapies
  • Integration with AI and Multi-Omics Platforms

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, pricing analysis, brand share analysis, consumer survey, demography analysis, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Transcriptomics Market Trends

Enhanced Discovery Through AI and Multi-Omics Integration

  • A significant and accelerating trend in the global transcriptomics market is the deepening integration with artificial intelligence (AI) and advanced multi-omics platforms, such as genomics, proteomics, and metabolomics. This convergence of technologies is revolutionizing how researchers interpret gene expression data, enabling faster, more accurate insights into complex biological processes and disease mechanisms
    • For instance, next-generation AI-powered analytics tools now assist researchers in analyzing massive RNA sequencing datasets to identify gene expression signatures linked to specific diseases. These platforms can predict transcriptomic patterns, suggest druggable targets, and even model disease progression based on temporal gene activity
  • AI integration in transcriptomics enhances the accuracy and speed of data interpretation, automates quality control, and reduces manual errors. Advanced machine learning algorithms are being developed to detect novel RNA variants, alternative splicing events, and non-coding RNA roles, which were previously difficult to identify with conventional methods
  • The seamless combination of transcriptomics with other omics data through AI platforms facilitates a systems biology approach, offering centralized insights into disease pathways. This unified view allows researchers to explore gene expression in conjunction with protein abundance and metabolic flux, dramatically improving biomarker discovery and therapeutic targeting
  • This trend toward intelligent, automated, and interconnected transcriptomic platforms is reshaping expectations in life sciences research. As a result, companies are investing in AI-enhanced transcriptomics solutions that integrate cloud-based analysis, intuitive visualization, and predictive modeling capabilities for use in both research and clinical settings
  • The demand for transcriptomics platforms that offer robust AI integration and cross-omics compatibility is rapidly increasing across pharmaceutical, academic, and diagnostic sectors, as stakeholders seek deeper biological insights, accelerated discovery timelines, and precision-driven outcomes in both research and healthcare applications

Transcriptomics Market Dynamics

Driver

“Growing Need Driven by Rising Demand for Precision Medicine and Genomic Research”

  • The increasing focus on precision medicine and personalized healthcare, along with the expanding applications of transcriptomics in disease diagnosis and drug development, is a key driver of market growth
    • For instance, in early 2024, several biotech firms announced collaborations to develop AI-powered transcriptomics platforms aimed at improving cancer biomarker discovery and therapeutic target identification. Such initiatives are expected to significantly boost the Transcriptomics market during the forecast period
  • As researchers and clinicians seek deeper insights into gene expression patterns linked to complex diseases, transcriptomics provides critical data that enhances diagnostic accuracy and treatment customization
  • Furthermore, the surge in government funding for genomics and transcriptomics research, alongside growing investments by pharmaceutical companies, is accelerating adoption across academic, clinical, and industrial settings
  • The increasing availability of affordable, high-throughput sequencing technologies and user-friendly bioinformatics tools is also propelling the use of transcriptomics solutions in both research labs and clinical diagnostics, contributing to widespread market expansion

Restraint/Challenge

Data Complexity, High Costs, and Regulatory Hurdles

  • The complexity and volume of transcriptomic data pose significant challenges for data analysis and interpretation, often requiring sophisticated bioinformatics infrastructure and expertise, which can limit adoption in smaller labs or emerging markets
    • For instance, the high cost associated with RNA sequencing platforms, reagents, and computational tools can be a barrier for budget-conscious research institutions and healthcare providers, particularly in developing regions
  • Moreover, the lack of standardized regulatory frameworks for clinical transcriptomics applications can delay market entry and clinical adoption, as companies must navigate rigorous validation and compliance processes
  • Addressing these challenges through the development of streamlined data analysis pipelines, cost-effective sequencing methods, and clear regulatory guidelines will be critical for broader market penetration
  • In addition, educating end users on the interpretation of transcriptomics data and demonstrating its clinical utility will help overcome skepticism and accelerate uptake in both research and clinical environments

Transcriptomics Market Scope

The market is segmented on the basis of product and services, technology, application, and end user.

By Product and Services

On the basis of product and services, the transcriptomics market is segmented into instruments, consumables, software, and services. The consumables segment dominates market with a market share of 38.6% in 2024, primarily due to the high recurring demand for reagents, kits, and probes in transcriptomic workflows, particularly in large-scale gene expression studies and clinical diagnostics.

Software segment is expected to witness the fastest CAGR of 19.3% from 2025 to 2032 due to increasing adoption of AI-powered data analytics and cloud-based bioinformatics tools facilitating complex data interpretation.

  • By Application

On the basis of application, the market is segmented into Therapeutics, Agriculture, Diagnostics, and Others. The Therapeutics segment dominates the largest market revenue share, estimated at around 40-45% in 2024. This dominance is driven by the significant investments in gene therapy research and development for treating a wide range of genetic disorders, cancers, and infectious diseases, offering the potential for curative treatments.

The Therapeutics segment is also anticipated to witness the fastest growth rate, projected at around 15-18% CAGR from 2025 to 2032. This rapid growth is fueled by increasing regulatory approvals for gene-edited therapies, a growing pipeline of clinical trials, and the expanding scope of diseases addressable by gene editing.

  • By Workflow

On the basis of workflow, the market is segmented into CRISPR-based Workflow, ZFN-based Workflow, and Others. The CRISPR-based Workflow segment held the largest market revenue share, estimated at around 70-75% in 2024. This is driven by the inherent advantages of CRISPR, including its simplicity, cost-effectiveness, and high efficiency, which have made it the go-to tool for a vast majority of gene editing experiments and applications.

The CRISPR-based Workflow segment is expected to witness the fastest CAGR, projected at around 14-17% from 2025 to 2032. This growth is propelled by continuous innovations in CRISPR variants (e.g., base editing, prime editing), expansion into new therapeutic areas, and increased adoption in industrial and agricultural biotechnology workflows.

  • By Delivery Method

On the basis of delivery method, the market is segmented into Viral Delivery, Non-viral Delivery, and Others. The Viral Delivery segment held the largest market revenue share, estimated at around 55-60% in 2024. This dominance is due to the high efficiency of viral vectors (such as AAVs and lentiviruses) in delivering gene editing components into target cells, which is crucial for therapeutic applications requiring stable and robust gene modification.

The Non-viral Delivery segment is expected to witness the fastest CAGR, projected at around 10-12% from 2025 to 2032. This growth is driven by ongoing research into safer, more scalable, and less immunogenic non-viral methods (e.g., lipid nanoparticles, electroporation), aiming to overcome some limitations of viral vectors for broad clinical application.[DS1] 

Transcriptomics Market Regional Analysis

  • North America dominates the transcriptomics market with the largest revenue share of 38.5% in 2024, driven by increased investment in genomic research, rising healthcare expenditure, and a strong presence of key industry players specializing in transcriptomic technologies
  • Researchers and clinicians in the region benefit from advanced infrastructure and widespread adoption of next-generation sequencing and real-time PCR platforms, which support applications ranging from disease diagnostics to drug development
  • This robust market position is further bolstered by government funding initiatives, collaborations between academic institutions and biotech firms, and the rapid integration of AI-based bioinformatics tools that enhance data interpretation and accelerate discovery in both academic and commercial settings

U.S. transcriptomics market insight

The U.S. transcriptomics market captured the largest revenue share of 78.2% in 2024 within North America, driven by rapid advancements in genomic research technologies and strong investment in precision medicine. Increasing demand for disease profiling and drug discovery applications fuels the market, supported by leading biotech firms and research institutions. Furthermore, integration of AI-powered bioinformatics tools enhances data analysis, promoting wider adoption of transcriptomics in both clinical and pharmaceutical sectors.

Europe transcriptomics market insight

The Europe transcriptomics market is projected to grow at a substantial CAGR during the forecast period, supported by government initiatives promoting genomic research and healthcare innovation. Rising funding for personalized medicine and growing collaborations between pharmaceutical companies and academic centers foster market expansion. Stringent regulatory frameworks and increasing healthcare expenditure also drive demand for transcriptomic diagnostics and drug development services.

U.K. transcriptomics market insight

The U.K. transcriptomics market is expected to expand at a notable CAGR over the forecast period, driven by increased adoption of precision medicine and ongoing government support for genomic initiatives. The country’s well-established biotech sector, combined with investments in clinical research infrastructure, is accelerating transcriptomics applications in diagnostics and drug discovery. The strong presence of contract research organizations (CROs) further enhances market growth.

Germany transcriptomics market insight

Germany’s transcriptomics market is forecasted to grow at a significant CAGR, propelled by strong research activities in genomics and growing adoption of transcriptomics in pharmaceutical R&D. Increasing collaborations between government institutes and biotech companies, along with emphasis on sustainable healthcare innovation, support market expansion. The demand for advanced transcriptomic instruments and bioinformatics software is steadily increasing across research and clinical settings.

Asia-Pacific transcriptomics market insight

The Asia-Pacific transcriptomics market is anticipated to register the fastest CAGR of 13.4% between 2025 and 2032, fueled by expanding biotech and pharmaceutical sectors in China, India, and Japan. Government initiatives focused on digital health and genomics, alongside rising healthcare spending and technological advancements, boost market penetration. The availability of affordable transcriptomic tools and growing academic research further contribute to rapid growth.

Japan transcriptomics market insight

Japan’s transcriptomics market is gaining momentum, supported by a high level of technological innovation and a strong focus on aging population healthcare solutions. Increasing integration of transcriptomics with other omics technologies for comprehensive disease analysis drives adoption. The country’s commitment to smart healthcare and precision medicine enhances demand across clinical and pharmaceutical research applications.

China transcriptomics market insight

China accounted for the largest revenue share in the Asia-Pacific transcriptomics market in 2024, driven by its expanding middle-class population, rapid urbanization, and increased investment in biotech infrastructure. The country’s push toward becoming a global hub for genomics research, supported by favorable government policies and domestic manufacturing capabilities, accelerates transcriptomics adoption. Growing collaborations between academic institutions and industry players also underpin market growth.

Transcriptomics Market Share

The transcriptomics industry is primarily led by well-established companies, including:

Latest Developments in Global Transcriptomics Market

  • In May 2025, Thermo Fisher Scientific Inc. announced the launch of its next-generation RNA sequencing platform designed to enhance transcriptomic profiling capabilities in clinical research. The platform integrates automation and cloud-based analytics, enabling researchers to conduct high-throughput transcriptome analysis with greater efficiency and reproducibility. This innovation underscores Thermo Fisher’s commitment to advancing precision medicine through powerful omics technologies
  • In April 2025, Illumina, Inc. collaborated with a leading academic consortium in Europe to develop AI-driven transcriptomics tools for cancer diagnostics. The partnership aims to harness machine learning algorithms to identify gene expression signatures associated with early-stage tumors, accelerating the development of personalized treatment protocols. This initiative is part of Illumina's broader push to integrate AI into its genomics ecosystem
  • In March 2025, Qiagen launched a new range of multiplex PCR kits optimized for transcriptomic biomarker discovery in autoimmune and neurodegenerative diseases. The kits are designed for use in translational research and clinical trials, offering enhanced sensitivity and reproducibility for low-expressing genes. The development marks Qiagen’s strategic expansion into disease-specific transcriptomic solutions
  • In February 2025, 10x Genomics unveiled its Spatial Molecular Imager (SMI) for advanced tissue transcriptomics, capable of mapping gene expression at subcellular resolution. The system, tailored for oncology and immunology research, provides spatial context to transcriptomic data, unlocking deeper insights into tissue microenvironments. This innovation is expected to significantly advance biomarker discovery and therapeutic development
  • In January 2025, Takara Bio Inc. announced the commercial availability of its Smart-seq Single Cell Transcriptomics Kit, which simplifies high-throughput single-cell RNA sequencing workflows. The kit, compatible with leading sequencing platforms, targets researchers in immunology and stem cell biology. The launch supports Takara Bio’s vision of democratizing access to single-cell technologies in both academic and clinical research setting

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

North America region holds the largest share in the market.
The countries covered in the transcriptomics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
The major players covered in the transcriptomics market report are Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc, Thermo Fisher Scientific, BD, Biological Industries, bioMérieux SA, Bio-Rad Laboratories, Inc, Cepheid, Takara Bio Inc., Cytognomix, Edico Genome (subsidiary of Illumina, Inc.), GENERAL ELECTRIC COMPANY, Siemens, QIAGEN, Merck KGaA, Kapa Biosystems, Spatial Transcriptomics, and NanoString Technologies, Inc.
Testimonial